ICICI Direct has given Buy recommendation for Jubilant Pharmova with a target price of Rs. 850 in its research report issued on Jul 24, 2021

ICICI Direct’s research report on Jubilant Pharmova

Jubilant Pharmova is engaged in specialty pharmaceuticals, CDMO, generics, drug discovery and proprietary novel drug businesses. Formulations – 24% of FY21 revenues, Radiopharma and allergy therapy – 38%, and CDMO & API – 33% of sales It has six USFDA approved manufacturing facilities in India, US and Canada

Outlook

Despite regulatory concerns, we remain positive and retain our BUY rating on the stock  We value Jubilant at Rs 850 i.e. 10x P/E on FY23E EPS

 

Leave a Reply

Your email address will not be published. Required fields are marked *